Interobserver variability for retreatment indications after Ranibizumab loading doses in neovascular age-related macular degeneration

被引:12
作者
Framme, Carsten [1 ,2 ]
Panagakis, Georgios [2 ]
Walter, Andreas [2 ]
Gamulescu, Maria Andreea [2 ]
Herrmann, Wolfgang [2 ]
Helbig, Horst [2 ]
机构
[1] Univ Eye Hosp Bern, CH-3010 Bern, Switzerland
[2] Univ Eye Hosp Regensburg, Regensburg, Germany
关键词
age-related macular degeneration; Anti-VEGF; choroidal neovascularization; intravitreal injection; Lucentis; Ranibizumab; spectral domain optical coherence tomography; CHOROIDAL NEOVASCULARIZATION;
D O I
10.1111/j.1755-3768.2010.01940.x
中图分类号
R77 [眼科学];
学科分类号
100212 [眼科学];
摘要
Purpose: To assess the interobserver variability (IOV) in indicating retreatment for neovascular Age-related macular degeneration 4 weeks after three Ranibizumab loading doses using spectral domain OCT (SD-OCT) as the primary objective diagnostic tool. Material and methods: Four observers decided for or against 4th Ranibizumab injection in 108 patients by six different rating rounds (RR) based on the SD-OCT findings after the loading doses. Postoperative OCT images were supplemented consecutively with information from a chart review as the 'patients subjective estimation of vision (SE)', the course of best-corrected visual acuity (BCVA) and the preoperative OCT as well as all information collectively. Agreement rates (AR) and Kappa statistics were calculated. Results: Based on post-treatment OCT findings only (RR1), mean reinjection rate of all observers was 37.5%. Adding supplementary information, mean reinjection rate decreased to 20% when all information was available reflecting the 'real' situation (RR 6). Interobserver agreement rates varied from 66.7% to 90.7% depending on rating rounds and interobserver pairs. Mean AR and Kappa values (KV) were as following: AR 81.6%, KV 0.61 (RR1: 'only post-OP OCT'); AR 76.7%, KV 0.33 (RR2: post-OP OCT + SE); AR 80.3%, KV 0.45 (RR3: post-OP OCT + BCVA); AR 80.7%, KV 0.46 (RR4: pre- and post-OP OCT); AR 82.2%, KV 0.49 (RR5: post-OP OCT + SE + BCVA); and finally AR 83.6%, KV 0.47 (RR6: pre- and post-OP OCT + SE + BCVA). The overall mean agreement rate was 80.9% with a Kappa of 0.47. Conclusion: IOV for indicating retreatment after three Ranibizumab loading doses reveals only moderate agreement in Kappa statistics, which seems to be too low considering the high costs for retreatments. More concise guidelines based on the post-treatment OCT scans as the presumably most sensitive and noninvasive objective tool to follow choroidal neovascularization activity by judging the course of sub- and intraretinal fluid are necessary.
引用
收藏
页码:49 / 55
页数:7
相关论文
共 21 条
[1]
Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: The Second Year of a Prospective Study [J].
Bashshur, Ziad F. ;
Haddad, Zeina A. ;
Schakal, Alexandre R. ;
Jaafar, Rola F. ;
Saad, Alain ;
Noureddin, Baha' N. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (01) :59-65
[2]
Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
[3]
Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
[4]
Ranibizumab versus verteporfin for neovascular age-related macular degeneration [J].
Brown, David M. ;
Kaiser, Peter K. ;
Michels, Mark ;
Soubrane, Gisele ;
Heier, Jeffrey S. ;
Kim, Robert Y. ;
Sy, Judy P. ;
Schneider, Susan .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1432-1444
[5]
Effects on Choroidal Neovascularization after Anti-VEGF Upload Using Intravitreal Ranibizumab, as Determined by Spectral Domain-Optical Coherence Tomography [J].
Framme, Carsten ;
Panagakis, Georgios ;
Birngruber, Reginald .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (03) :1671-1676
[6]
Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
[7]
Golbaz I, 2009, OPHTHALMOLOGE, V106, P1103, DOI 10.1007/s00347-008-1880-2
[8]
Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration [J].
Keane, Pearse A. ;
Liakopoulos, Sandra ;
Ongchin, Sharel C. ;
Heussen, Florian M. ;
Msutta, Sandeep ;
Chang, Karen T. ;
Walsh, Alexander C. ;
Sadda, Srinivas R. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2008, 49 (07) :3115-3120
[9]
Evaluation of Ranibizumab-Induced Changes in High-Resolution Optical Coherence Tomographic Retinal Morphology and Their Impact on Visual Function [J].
Kiss, Christopher G. ;
Geitzenauer, Wolfgang ;
Simader, Christian ;
Gregori, Giovanni ;
Schmidt-Erfurth, Ursula .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2009, 50 (05) :2376-2383
[10]
A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study [J].
Lalwani, Geeta A. ;
Rosenfeld, Philip J. ;
Fung, Anne E. ;
Dubovy, Sander R. ;
Michels, Stephen ;
Feuer, William ;
Davis, Janet L. ;
Flynn, Harry W., Jr. ;
Esquiabro, Maria .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (01) :43-58